{"id":"triumeq","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: HYPERSENSITIVITY REACTIONS, AND EXACERBATIONS OF HEPATITIS B Hypersensitivity Reactions Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ and TRIUMEQ PD (abacavir, dolutegravir, and lamivudine). Patients who carry the HLA ‑ B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA ‑ B*5701 a"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Insomnia","drugRate":"3%","severity":"moderate to severe","organSystem":""},{"effect":"Headache","drugRate":"2%","severity":"moderate to severe","organSystem":""},{"effect":"Fatigue","drugRate":"2%","severity":"moderate to severe","organSystem":""},{"effect":"Dizziness","drugRate":"5%","severity":"moderate to severe","organSystem":""},{"effect":"Nausea","drugRate":"3%","severity":"moderate to severe","organSystem":""},{"effect":"Diarrhea","drugRate":"2%","severity":"moderate to severe","organSystem":""},{"effect":"Depression","drugRate":"2%","severity":"moderate to severe","organSystem":""},{"effect":"Abnormal dreams","drugRate":"2%","severity":"moderate to severe","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Abacavir hypersensitivity reaction (serious/fatal)","drugRate":"","severity":"serious"},{"effect":"Dolutegravir hypersensitivity reaction","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Liver failure","drugRate":"","severity":"serious"},{"effect":"Renal failure","drugRate":"","severity":"serious"},{"effect":"Adult respiratory distress syndrome","drugRate":"","severity":"serious"},{"effect":"Respiratory failure","drugRate":"","severity":"serious"},{"effect":"Myolysis","drugRate":"","severity":"serious"},{"effect":"Death","drugRate":"","severity":"serious"},{"effect":"Erythema multiforme","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["abacavir/lamivudine/dolutegravir","dolutegravir (50mg)","abacavir (600mg)","lamivudine (300mg)"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Triumeq","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:12:01.872660+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:12:14.668672+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:12:07.156242+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Triumeq","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:12:07.510151+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 integrase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:12:08.574473+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1213165/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:12:08.223918+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"2997739a-aa91-42aa-a206-a70e2db7b84f","title":"TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE) TABLET, FILM COATED TRIUMEQ PD (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE) KIT [VIIV HEALTHCARE COMPANY]"},"aiSummary":"Triumeq, marketed by St Stephens Aids Trust, is an established antiretroviral therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.","ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:14:49.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:12:14.668745+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT06658977","phase":"PHASE3","title":"RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2024-11-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":12},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT02659761","phase":"PHASE4","title":"Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-11","conditions":"Human Immunodeficiency Virus","enrollment":33},{"nctId":"NCT03760458","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-09-09","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT04827134","phase":"PHASE1","title":"A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-05-07","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT05351684","phase":"PHASE2","title":"Effect of Dolutegravir Intensification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-01-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT05030025","phase":"EARLY_PHASE1","title":"Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-08-01","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT02569346","phase":"PHASE1","title":"Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-03","conditions":"HIV","enrollment":22},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02354053","phase":"PHASE4","title":"Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-11","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT03441984","phase":"PHASE1","title":"To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-02-26","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT02868580","phase":"PHASE2","title":"Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2016-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":43},{"nctId":"NCT02342769","phase":"","title":"Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-02-19","conditions":"HIV Infections","enrollment":403},{"nctId":"NCT02596334","phase":"PHASE3","title":"Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2015-12-23","conditions":"HIV","enrollment":158},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT03275701","phase":"NA","title":"Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC","status":"UNKNOWN","sponsor":"Mills Clinical Research","startDate":"2016-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT02893488","phase":"PHASE1","title":"Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-09-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":20},{"nctId":"NCT02067767","phase":"PHASE2","title":"Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-02","conditions":"HIV-1 Infection","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1213165"},"formularyStatus":[],"_approvalHistory":[{"date":"20230615","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215413"},{"date":"20220330","type":"ORIG","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215413"},{"date":"20251028","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215413"},{"date":"20240418","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215413"},{"date":"20221007","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA215413"},{"date":"20150928","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20170327","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20150805","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20221007","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20210301","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20230615","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20180906","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20200324","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20180511","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20160421","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20140822","type":"ORIG","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20171121","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20150615","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20220330","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20251028","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20210323","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20240418","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20190503","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20191024","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20180906","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"},{"date":"20160401","type":"SUPPL","sponsor":"VIIV HLTHCARE","applicationNumber":"NDA205551"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":45,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Triumeq","genericName":"Triumeq","companyName":"St Stephens Aids Trust","companyId":"st-stephens-aids-trust","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:12:14.668745+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}